Oxigene raises $15.18 million via at-market issuance sales agreement

McNicoll, Lewis & Vlak helps sell shares to public through offering

By Devika Patel

Knoxville, Tenn., June 29 - Oxigene Inc. raised $15.18 million in a public sale of its stock over the past year, according to an 8-K filed Wednesday with the Securities and Exchange Commission. The At Market Issuance Sales Agreement was conducted via agent McNicoll, Lewis & Vlak LLC.

Oxigene also filed a prospectus supplement which will allow it to sell up to $4 million more of its shares under this agreement.

The offering, which priced July 21, 2010, originally was for up to $4.79 million, but was increased on Jan. 31, June 1 and June 29.

Oxigene is a pharmaceutical company located in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.